Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HM |
| 1 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | not yet recruiting | Phase 2 | 99 | Washington University School of MedicineOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT01269853 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | recruiting | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01386710 | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | suspended | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03897491 | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma | terminated | Phase 2 | 17 | photonamic GmbH & Co. KGINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT06264388 | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | recruiting | Phase 2 | 33 | Ashish ShahOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07605364 | Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer | not yet recruiting | Phase 2 / Phase 3 | 422 | Alliance for Clinical Trials in OncologyOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab(DERIVe) | active not recruiting | Phase 2 | 43 | Annick Desjardins, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT00906893 | Evaluation of [18F]-FMISO for Non Operated Glioblastoma(MISOGLIO) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | terminated | Phase 1 / Phase 2 | 70 | VBI Vaccines Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05629702 | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids(ARISTOCRAT) | recruiting | Phase 2 | 120 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06649851 | G-CSF After Chemo-radiation in Patients With Glioblastoma | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07297212 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma | recruiting | Phase 2 | 75 | BioNTech SEINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05565521 | UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly(UNITED2) | active not recruiting | Phase 2 | 55 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | completed | Phase 2 / Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06336291 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence(GLIOSTELLA) | active not recruiting | Phase 2 | 90 | Philogen S.p.A.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04817254 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | active not recruiting | Phase 2 | 252 | CNS Pharmaceuticals, Inc.INDUSTRY | 5 | Apr 15, 2026 | clinicaltrials |
| NCT02866747 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma(STERIMGLI) | completed | Phase 1 / Phase 2 | 108 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients(STAR-GBM) | recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02800486 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | recruiting | Phase 2 | 37 | Northwell HealthOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07301268 | GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | recruiting | Phase 2 | 36 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma(PRISM) | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05986851 | Azeliragon in MGMT Unmethylated Glioblastoma | active not recruiting | Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04559230 | Sacituzumab Govitecan in Recurrent Glioblastoma | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04574856 | Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma(TEMPO) | recruiting | Phase 2 | 118 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05753007 | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | terminated | Phase 2 | 2 | Mclean HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03475186 | Testing Ramipril to Prevent Memory Loss in People With Glioblastoma | completed | Phase 2 | 75 | Wake Forest University Health SciencesOTHER | 2 | Mar 13, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2026source: clinicaltrials